You are here

Home › AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial › AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial

AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial

Primary tabs

AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial

Wed, 2021-09-29 19:44 — mike kraft
AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial AstraZeneca Plc's COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 and older, according to long-awaited results of the company's U.S. clinical trial published on Wednesday. Julie Steenhuysen Reuters

CHICAGO, Sept 29 (Reuters) -

The data looked at more than 26,000 volunteers in the United States, Chile and Peru, who received two doses of the vaccine spaced about a month apart. The results were published in the New England Journal of Medicine. ...

Country / Region Tags: 
Global
United Kingdom
United States
General Topic Tags: 
COVID-19
Data
Medical Testing
Vaccinations
Contagion
Disease
Government
Health
Pandemics
Research
Problem, Solution, SitRep, or ?: 
Situation Report
Groups this Group Post belongs to: 
Global Health
UK Resilience
Vaccines
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.463 seconds.